Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography

Area of Science:

• Nuclear Medicine
• Oncology
• Molecular Imaging

Background:

• Positron Emission Tomography (PET) is a powerful imaging technique for visualizing biological processes.
• Malignant transformation involves complex molecular pathways that can be targeted for monitoring.
• Radiolabeling biological probes allows for in vivo imaging of specific targets.

Purpose of the Study:

• To review the application of PET imaging in monitoring key pathways of malignant transformation.
• To highlight various radiolabeled compounds and their corresponding biological targets.
• To demonstrate the versatility of PET in assessing different aspects of cancer biology.

Main Methods:

• Utilizing radiolabeled compounds for PET imaging.
• Targeting ligand-receptor interactions with 16alpha-[(18)F]fluoro-17beta-oestradiol (FES).
• Monitoring metabolism with [(18)F]fluorodeoxy-glucose ([(18)F]FDG) and signal transduction with (11)C-methyl-choline.
• Assessing cell cycle/proliferation using 2-[(11)C]thymidine, cell death with [(124)I]annexin V, drug resistance with [(124)C]colchicine, and angiogenesis with [(124)I]anti-VEGF.

Main Results:

• PET can effectively monitor diverse biological pathways relevant to cancer.
• Specific radiotracers are available for imaging estrogen receptor status (FES), glucose metabolism (FDG), choline metabolism, thymidine incorporation, apoptosis (annexin V), drug resistance (colchicine), and angiogenesis (anti-VEGF).
• These PET applications provide valuable insights into tumor behavior and progression.

Conclusions:

• PET imaging, with its array of radiolabeled probes, is a versatile tool for monitoring malignant transformation.
• It allows for non-invasive assessment of critical cellular processes from metabolism to angiogenesis.
• PET facilitates a comprehensive understanding of tumor biology, aiding in diagnosis and treatment monitoring.